Authors:
Sandmair, AM
Loimas, S
Puranen, P
Immonen, A
Kossila, M
Puranen, M
Hurskainen, H
Tyynela, K
Turunen, M
Vanninen, R
Lehtolainen, P
Paljarvi, L
Johansson, R
Vapalahti, M
Yla-Herttuala, S
Citation: Am. Sandmair et al., Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses, HUM GENE TH, 11(16), 2000, pp. 2197-2205
Authors:
Sandmair, AM
Turunen, M
Tyynela, K
Loimas, S
Vainio, P
Vanninen, R
Vapalahti, M
Bjerkvig, R
Janne, J
Yla-Herttuala, S
Citation: Am. Sandmair et al., Herpes simplex virus thymidine kinase gene therapy in experimental rat BT4C glioma model: Effect of the percentage of thymidine kinase-positive glioma cells on treatment effect, survival time, and tissue reactions, CANC GENE T, 7(3), 2000, pp. 413-421
Authors:
Visted, T
Thorsen, J
Thorsen, F
Read, TA
Ulvestad, E
Engebraaten, O
Sorensen, D
Yla-Herttuala, S
Tyynela, K
Rucklidge, G
Edvardsen, K
Bjerkvig, R
Lund-Johansen, M
Citation: T. Visted et al., lacZ-neoR transfected glioma cells in syngeneic rats: Growth pattern and characterization of the host immune response against cells transplanted inside and outside the CNS, INT J CANC, 85(2), 2000, pp. 228-235
Authors:
Sandmair, AM
Loimas, S
Poptani, H
Vainio, P
Vanninen, R
Turunen, M
Tyynela, K
Vapalahti, M
Yla-Herttuala, S
Citation: Am. Sandmair et al., Low efficacy of gene therapy for rat BT4C malignant glioma using intra-tumoural transduction with thymidine kinase retrovirus packaging cell injections and ganciclovir treatment, ACT NEUROCH, 141(8), 1999, pp. 867-872